following an abbreviated submission:
vanzacaftor/tezacaftor/deutivacaftor (Alyftrek®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
SMC restriction: patients aged 6 years and older who have at least one F508del mutation in the CFTR gene.
Vanzacaftor/tezacaftor/deutivacaftor (Alyftrek®) offers an additional treatment choice in the therapeutic class of CFTR modulators.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice373KB (PDF)
Medicine details
- Medicine name:
- vanzacaftor / tezacaftor / deutivacaftor (Alyftrek)
- SMC ID:
- SMC2800
- Indication:
For the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
- Pharmaceutical company
- Vertex Pharmaceuticals Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 09 March 2026